Biology subjects

Shapira, T.

Publications and source records attributed to Shapira, T..

3 recordsLinked to original sources

bioRxiv2026

Trans-regenerational RNAi Memory in Planarians

How cells and organisms preserve molecular memory is a central question in biology. Chromatin states can maintain cellular memory in animals, yet DNA and histone modifications are typically reset in the germ line and early embryo. In Caenorhabditis elegans, RNA-dependent RNA polymerases (RdRPs) amplify small RNAs and enable transgenerational gene regulation. However, many organisms, including mammals, lack canonical RdRPs. Here we find that planarians, highly regenerative flatworms that lack canonical RdRPs and critical nuclear RNAi machinery, mount long-term heritable gene regulatory responses. We show that ingestion of double-stranded RNA induces potent, sequence-specific silencing that persists for months, withstands repeated cycles of whole-body regeneration, and can be transferred between animals. This long-term silencing, heritable during asexual reproduction, follows two phases: an early, transient response to exogenous RNA, and a stable, cell-autonomous memory phase that maintains repression long after the RNA trigger is gone. The memory phase is maintained post-transcriptionally, as transcription and chromatin accessibility remain unchanged while mature mRNA is depleted. This phase coincides with the emergence of A-tailed 21-23-nt antisense small RNAs and with silencing responses that act in trans and spread across the length of the target transcript. These results reveal a two-step, canonical RdRP-independent mechanism for persistent RNAi memory in a regenerating animal and establish planarians as a model for RNA-based inheritance, illuminating a novel mode by which RNA can encode durable gene-silencing states in metazoans.

developmental biology↗

bioRxiv2024

The diversity of clinical Mycobacterium abscessus isolates in morphology, glycopeptidolipids and infection rates in a macrophage model

Mycobacterium abscessus (Mab) colonies adopt smooth (S) or rough (R) morphotypes, which are linked to the presence or absence of glycopeptidolipids (GPL), respectively. Though clinically relevant, the association between GPL levels, morphotype and pathogenesis are poorly understood. To investigate the degree of correlation between Mab morphology, GPL levels, and infectivity, we generated isolates from Mab-positive sputum samples from cystic fibrosis patients. Isolated strains were categorised based on their morphology, GPL profile, and replication rate in macrophages. Our findings revealed that around 50% of isolates displayed mixed morphologies and GPL analysis confirmed a consistent relationship between GPL content and morphotype was only found in smooth isolates. Across morphotype groups, no differences were observed in vitro, yet using a high-content THP-1 cell ex vivo infection model, clinical R strains were observed to replicate at higher levels. Moreover, the proportion of infected macrophages was notably higher among clinical R strains compared to their S counterparts at 72 hours post-infection. Clinical variants also infected at significantly higher rates compared to laboratory strains, highlighting the limited translatability of lab strain infection data to clinical contexts. Our study confirmed the general correlation between morphotype and GPL levels in smooth strains yet unveiled more variability within morphotype groups than previously recognised, particularly during intracellular infection. As the rough morphotype is of highest clinical concern, these findings contribute to the expanding knowledge base surrounding Mab infections, offering insights that can steer diagnostic methodologies, and treatment approaches.

microbiology↗

bioRxiv2021

A novel highly potent inhibitor of TMPRSS2-like proteases blocks SARS-CoV-2 variants of concern and is broadly protective against infection and mortality in mice

The COVID-19 pandemic caused by the SARS-CoV-2 virus remains a global public health crisis. Although widespread vaccination campaigns are underway, their efficacy is reduced against emerging variants of concern (VOCs) 1,2. Development of host-directed therapeutics and prophylactics could limit such resistance and offer urgently needed protection against VOCs 3,4. Attractive pharmacological targets to impede viral entry include type-II transmembrane serine proteases (TTSPs), such as TMPRSS2, whose essential role in the virus lifecycle is responsible for the cleavage and priming of the viral spike protein 5-7. Here, we identify and characterize a small-molecule compound, N-0385, as the most potent inhibitor of TMPRSS2 reported to date. N-0385 exhibited low nanomolar potency and a selectivity index of >106 at inhibiting SARS-CoV-2 infection in human lung cells and in donor-derived colonoids 8. Importantly, N-0385 acted as a broad-spectrum coronavirus inhibitor of two SARS-CoV-2 VOCs, B.1.1.7 and B.1.351. Strikingly, single daily intranasal administration of N-0385 early in infection significantly improved weight loss and clinical outcomes, and yielded 100% survival in the severe K18-human ACE2 transgenic mouse model of SARS-CoV-2 disease. This demonstrates that TTSP-mediated proteolytic maturation of spike is critical for SARS-CoV-2 infection in vivo and suggests that N-0385 provides a novel effective early treatment option against COVID-19 and emerging SARS-CoV-2 VOCs.

microbiology↗